H. Lee Moffitt Cancer Center and Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).
H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.
H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
502 total, page 3 of 11
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
NCT05628883
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
NCT05692596
Early Supportive Care and Nutritional Support in Adults With Pancreatic Cancer
NCT05438927
Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients
NCT05438940
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
NCT05358938
"COACH" Study: Individualized COaching in Young Adult Cancer Survivors to Encourage Healthy Behaviors
NCT05434702
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
NCT05271630
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
NCT05015426
Preop fSRS for Resectable Brain Metastases
NCT05267587
DASH INtervention to INvestigate the Gut
NCT04538482
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
NCT05177211
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
NCT04879940
First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer
NCT05189457
Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma
NCT05108428
Automated Video-Assisted Smoking Treatment for People Living With HIV
NCT05014282
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
NCT05170334
Partnering With Food Bank to Provide Tobacco Treatment to Underserved Smokers
NCT05004662
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
NCT04975152
Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer
NCT05064085
Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools
NCT04335799
Evaluating Stress Management Among Allogeneic HCT Caregivers
NCT05078229
NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies
NCT04955730
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
NCT04869137
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
NCT04863885
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA
NCT04798339
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
NCT04745559
Evolutionary Therapy for Rhabdomyosarcoma
NCT04388839
Clinical Trial of Green Tea Catechins in Men on Active Surveillance
NCT04300855
Quality of Life Model for Older Patients With AML
NCT04380441
Colorectal Cancer Awareness, Research and Education and Screening - Rural Expansion, Access and Capacity for Health
NCT04464668
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
NCT04151667
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
NCT03610971
Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
NCT03628209
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
NCT04069299
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
NCT03722407
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
NCT03923270
Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers
NCT03598309
Florida Pancreas Collaborative Next Generation Biobank
NCT03851133
Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC
NCT03611738
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
NCT03614949
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
NCT03543189
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
NCT03511196
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT03543969
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT03387553
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
NCT03384914
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
NCT03377023
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
NCT03071406
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
NCT02721459
Validation Study on the Impact of Decipher® Testing - VANDAAM Study
NCT02723734
Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
NCT02638090
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 167 |
| Phase 2 | 168 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline
82 recruiting of 502 indexed (16% open); 280 completed (56%).
Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide
Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 502 trials (± recruiting share)
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Case Western Reserve University · 16% recruiting · 141 trials
- Drexel University · 16% recruiting · 92 trials
- Atlantic Health System · 16% recruiting · 43 trials
- BioMarin Pharmaceutical · 16% recruiting · 80 trials
Related
What to do with this H. Lee Moffitt Cancer Center and Research Institute page
502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.
- 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets.Report a data error.